

Expression of Urinary miRNA as a Potential Biomarker for Bladder Cancer Diagnosis

Thesis

Submitted For Partial Fulfillment of
Master Degree in Medical Biochemistry and Molecular Biology

By

Esraa Mohamed Ali

Demonstrator of Medical Biochemistry and Molecular Biology
(M.B., B.Ch)

Faculty of Medicine - Ain Shams University

Supervised By

Prof. Dr. Sanaa Eissa Mohamed

Professor of Medical Biochemistry and Molecular Biology
Faculty of Medicine
Ain Shams University.

Dr. Haidy Zakaria Habib

Lecturer of Medical Biochemistry and Molecular Biology
Faculty of Medicine
Ain Shams University.

Associate Prof. Dr. Mohamed Esmat Abbas

Associate Professor of Urology Department
Faculty of Medicine
Ain Shams University

Medical Biochemistry and Molecular Biology Department

**Faculty of Medicine
Ain Shams University**

2015

Contents

Subjects	Page
List of Contents	I
List of abbreviations	II
List of Figures	VII
List of Tables	VIII
• Introduction	1
• Aims of the Work	4
• Review of Literature	
♦ Bladder Cancer	5
♦ MicroRNA	32
♦ miRNA & Bladder Cancer	62
• Patients and Methods	73
• Results	93
• Discussion	110
• Conclusions	120
• Recommendations	122
• Summary	123
• References	127
• Arabic Summary	

List of Abbreviations

Abb.	Meaning
ADAM9	A disintegrin and metalloprotease domain 9
Ago2	Argonaute protein 2
AJCC	American Joint Committee on Cancer
BAX	BCL2-associated X protein
BC	Bladder cancer
BCL2	B-cell lymphoma 2 gene
BCLA	Bladder cancer-specific nuclear matrix protein
bp	Base pair
BPH	Benign prostatic hypertrophy
BTA	Bladder tumor antigen
BTA-stat	A test for early detection of bladder cancer
BTA-TRAK	An assay to diagnose transitional cell carcinoma of the bladder
CD44	A cell surface glycoprotein
CDK	Cyclin dependent kinase
cDNA	Complementary DNA
CEACAM1	Carcinoembryonic antigen-related cell adhesion molecule
CertNDx	Bladder cancer assay test includes three types of tests; Hematuria Assessment, Molecular Grading, and Recurrence Monitoring.
CIS	Carcinoma in situ
c-MYC	Myelocytomatosis oncogene
CT	Computed tomography
CxBladder	A non-invasive bladder cancer detection test
DD23	Tumor-associated antigen for bladder cancer detection and recurrence monitoring.

List of Abbreviations

*Abbreviations are listed in alphabetical order by the first letter of the abbreviation. The list is not exhaustive and is subject to change. The list is provided for reference only and does not constitute a guarantee of accuracy or completeness. The list is not intended to be used as a substitute for a medical dictionary or other reference source. The list is not intended to be used as a substitute for a medical dictionary or other reference source.

Abb.	Meaning
DGCR8	DiGeorge syndrome chromosomal [or critical] region 8
DNA	Deoxynucleic acid
DNMT3A	DNA (cytosine-5-)-methyltransferase 3 alpha
ds	Double stranded
dsRNA	Double stranded RNA
FDA	US Food and Drug Administration
FDP	Fibrin/fibrinogen degradation products
FFPE	Formalin-fixed and paraffin embedded
FISH	Fluorescence in-situ hybridization
FOXO	Forkhead Box O subfamily of transcription factors
FSCN1	Fascin actin-bundling protein 1,
G1	Gap1 phase of cell cycle
GST	Glutathione S-transferase
GSTP1	Glutathione S-transferase P 1
HCC	Hepatocellular carcinoma
HDAC4	Histone deacetylase
HNPCC	Hereditary non-polyposis colorectal cancer
IARC	International Agency for Research on Cancer
ImmunoCyt/uCyt+	urinary marker assay with high sensitivity for the diagnosis of urothelial carcinoma (UC)
ISH	In situ hybridization
ISUP	International society of Urological Pathology
IVP	Intravenous pyelogram
IVU	Intravenous urogram
kb	kilo base

List of Abbreviations

*Abbreviations are listed in alphabetical order of the abbreviation, not the meaning. The list is not exhaustive and is subject to change as new abbreviations are added or existing ones are updated.

Abb.	Meaning
KRAS	Kirsten rat sarcoma viral oncogene
LASP1	LIM and SH3 domain protein 1
LCSs	Let-7 complementary sites
let-7	A family of miRNA originally discovered in the nematode <i>Caenorhabditis elegans</i>
LNA	Locked nucleic acid, oligonucleotides for the detection of small or highly similar DNA or RNA targets
M	Metastasis
MCL1	Induced myeloid leukemia cell differentiation protein
MDM-2	Mouse double minute 2 homolog
miRBase	microRNA database
miRISC	miRNA-induced silencing complex
miRNA	Micro RNA
MRI	Magnetic resonance imaging
mRNA	messenger RNA
N	Nodes
NAT	N-acetyltransferase
NMP-22	Nuclear matrix protein 22
NPV	Negative predictive value
NS	Non significance
NSCLC	Non-small cell lung cancer
nt	Nucleotide
P53	Tumor protein of 53Kilo Dalton
p53RE	p53 response element
PARP-1	Poly [ADP-ribose] polymerase 1

List of Abbreviations

* Abbreviations are used throughout the manuscript to represent various terms and concepts. The list of abbreviations is provided for reference.

Abb.	Meaning
SPSS	Statistical Package for the Social Sciences
SRF	Serum response factor
T	Tumor grade
TAGLN2	Transgelin 2
TCC	Transitional cell carcinoma
TGF-β1	Transforming growth factor beta 1
TNM	Tumor-Nodes-Metastasis
TPM1	Tropomyosin-1
TRBP	Transactivator RNA-binding protein
UTR	Untranslated region
WHO	World Health Organization

List of Figures

[illegible]

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	WHO 2004 Classification of Noninvasive and Invasive Urothelial Neoplasms.	8
<u>2</u>	Grading of Bladder Cancer.	16
<u>3</u>	Reverse-Transcription Reaction Components.	84
<u>4</u>	Reaction Mix for MiScript Primer Assays.	85
<u>5</u>	Cycling Conditions.	86
<u>6</u>	Serum Bilharzial Antibodies in Different Groups of the Study.	98
<u>7</u>	Positivity Rate of Bilharzial Antibodies in Relation to Different Clinicopathological Factors in Bladder Cancer Group.	99
<u>8</u>	Urine Cytology Results Among Different Groups of the Study.	100
<u>9</u>	Urine Cytology Pattern in Relation to Clinicopathological Factors in Bladder Cancer Group	101
<u>10</u>	Expression of miRNA-96 in Different Groups Based on RQ, Delta Ct & Delta Delta Ct Values	102
<u>11</u>	Expression of miRNA-96 in Different Groups Based on RQ Values.	104
<u>12</u>	miRNA 96 RQ Levels in Relation to Different Clinicopathological Factors of the Bladder Cancer Group	105

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>13</u>	Expression of Urinary miRNA-96 in Bilharzial Benign and Malignant Cases.	106
<u>14</u>	Combined Sensitivity, Specificity, Predictive Values and Accuracy of Investigated Urine Marker & Cytology for Detection of Bladder Cancer.	107
<u>15</u>	Combined Sensitivity, Specificity, Predictive Values and Accuracy of Investigated Urine Marker & Cytology in Early Stage Bladder Cancer.	108
<u>16</u>	Combined Sensitivity, Specificity, Predictive Values and Accuracy of Investigated Urine Marker & Cytology in Low Grade Bladder Cancer.	109



Introduction





Aim of the Work





Review of Literature





Patients and Methods





Results

